109942-70-3

Basic information

• Product Name: 3-(2-METHYL-PYRIDIN-4-YL)-PROPAN-1-OL
• Synonyms: 3-(2-METHYL-PYRIDIN-4-YL)-PROPAN-1-OL
• CAS NO: 109942-70-3
• Molecular Formula: C9H13NO
• Molecular Weight: 151.21
• Mol File: 109942-70-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 274.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.037±0.06 g/cm3(Predicted)
• PKA: 14.93±0.10(Predicted)
• CAS DataBase Reference: 3-(2-METHYL-PYRIDIN-4-YL)-PROPAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-METHYL-PYRIDIN-4-YL)-PROPAN-1-OL(109942-70-3)
• EPA Substance Registry System: 3-(2-METHYL-PYRIDIN-4-YL)-PROPAN-1-OL(109942-70-3)

Safety Data

• Hazardous Substances Data: 109942-70-3(Hazardous Substances Data)

Upstream product

• 63875-01-4 2-methyl-pyridine-4-carbaldehyde 

Relevant articles and documents

ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF

Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Discovery, Structure-Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

The metabotropic glutamate receptor 4 (mGluR4) is an emerging target for the treatment of Parkinson's disease (PD). However, since the discovery of its therapeutic potential, no ligand has been successfully developed enough to be tested in the clinic. In the present paper, we report for the first time the medicinal chemistry efforts conducted around the pharmacological tool (-)-PHCCC. This work led to the identification of compound 40, a potent and selective mGluR4 positive allosteric modulator (PAM) with good water solubility and demonstrating consistent activity across validated preclinical rodent models of PD motor symptoms after intraperitoneal administration: haloperidol-induced catalepsy in mouse and the rat 6-hydroxydopamine (6-OHDA) lesion model. Moreover, we also describe the identification of compound 60 a close analogue of compound 40 with improved pharmacokinetic profile after oral administration. On the basis of its favorable and unique preclinical profile, compound 60 (PXT002331, now foliglurax) was nominated as a candidate for clinical development.